Abzena hires Dr Campbell Bunce to new role of SVP Scientific Operations

Company: Abzena

Adds further immunology expertise to the Executive Management Team

Abzena, a UK life sciences group providing services and technologies that enable the development and manufacture of biopharmaceutical products, has appointed Dr Campbell Bunce to the new role of Senior Vice President, Scientific Operations.

Bunce will join Abzena’s Executive Management Team, reporting to John Burt, CEO. He will have responsibility for the immunology and protein engineering groups and will work alongside Chief Scientific Officer, Matthew Baker, to provide immunology expertise to support internal research and partners’ projects. He will be based in Abzena’s Cambridge office.

He joins the firm from Oxford Immunotec where he was General Manager, Immunology Products, having previously worked at Immune Targeting Systems as R&D Director.

You may also like

Research & Development

Abzena launches an analytical platform to accelerate antibody development

The standardised and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs
Drug Delivery

Abzena launches AbZelect platforms for improving cell line development efficiency on the pathway to IND

The platforms will enable Abzena to rapidly progress their customer’s complex biologic drug programs towards clinical trials while de-risking the journey to IND application
Research & Development

The fine art of drug formulation

When it comes to pharmaceuticals, formulation development is like a finely tuned art form; the scientific understanding of a drug’s intrinsic properties must be balanced with the practical challenges of delivering it. This process, often overshadowed by the more dramatic aspects of drug discovery, plays a pivotal role in transforming promising compounds into viable and effective medications
Research & Development

Abzena partners with FDA on publication demonstrating the benefits of the MAPPs assay for immunogenicity

Abzena, has coauthored a publication with the US Food and Drug Administration (FDA) demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk and help design superior antibody and biologics with a higher chance of a successful outcome in patients
Research & Development

Abzena Partners with ProteoNic to offer enhanced CHO cell line platform for complex biologics

Premium vector technology will improve the production of high-yielding mammalian cell lines
Research & Development

Abzena opens biologics testing lab in California

Tighter control of timelines will be possible at the facility, alongside rigorous evaluation of each integrated programme to provide appropriate data
Ingredients

Bispecific antibodies: an exciting new class of emerging therapeutics

Since 2015, when the first bispecific received US FDA approval, these game-changing antibodies have rocketed in popularity<sup>1</sup>, reports Simon Keen, VP of Cell Line Development at Abzena
Subscribe now